S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.81 (+0.00%)
AAPL   171.94 (-0.79%)
MSFT   421.22 (-0.05%)
META   489.33 (-0.92%)
GOOGL   151.15 (+0.19%)
AMZN   180.57 (+0.41%)
TSLA   176.12 (-2.06%)
NVDA   905.20 (+0.30%)
NIO   4.51 (-3.43%)
AMD   180.36 (+0.43%)
BABA   72.39 (+1.12%)
T   17.65 (+0.57%)
F   13.26 (+1.53%)
MU   117.96 (-0.99%)
CGC   8.63 (-9.63%)
GE   175.78 (-2.41%)
DIS   122.38 (+1.16%)
AMC   3.66 (-15.67%)
PFE   27.86 (+0.29%)
PYPL   67.25 (+1.02%)
XOM   116.08 (+0.97%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.81 (+0.00%)
AAPL   171.94 (-0.79%)
MSFT   421.22 (-0.05%)
META   489.33 (-0.92%)
GOOGL   151.15 (+0.19%)
AMZN   180.57 (+0.41%)
TSLA   176.12 (-2.06%)
NVDA   905.20 (+0.30%)
NIO   4.51 (-3.43%)
AMD   180.36 (+0.43%)
BABA   72.39 (+1.12%)
T   17.65 (+0.57%)
F   13.26 (+1.53%)
MU   117.96 (-0.99%)
CGC   8.63 (-9.63%)
GE   175.78 (-2.41%)
DIS   122.38 (+1.16%)
AMC   3.66 (-15.67%)
PFE   27.86 (+0.29%)
PYPL   67.25 (+1.02%)
XOM   116.08 (+0.97%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.81 (+0.00%)
AAPL   171.94 (-0.79%)
MSFT   421.22 (-0.05%)
META   489.33 (-0.92%)
GOOGL   151.15 (+0.19%)
AMZN   180.57 (+0.41%)
TSLA   176.12 (-2.06%)
NVDA   905.20 (+0.30%)
NIO   4.51 (-3.43%)
AMD   180.36 (+0.43%)
BABA   72.39 (+1.12%)
T   17.65 (+0.57%)
F   13.26 (+1.53%)
MU   117.96 (-0.99%)
CGC   8.63 (-9.63%)
GE   175.78 (-2.41%)
DIS   122.38 (+1.16%)
AMC   3.66 (-15.67%)
PFE   27.86 (+0.29%)
PYPL   67.25 (+1.02%)
XOM   116.08 (+0.97%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.81 (+0.00%)
AAPL   171.94 (-0.79%)
MSFT   421.22 (-0.05%)
META   489.33 (-0.92%)
GOOGL   151.15 (+0.19%)
AMZN   180.57 (+0.41%)
TSLA   176.12 (-2.06%)
NVDA   905.20 (+0.30%)
NIO   4.51 (-3.43%)
AMD   180.36 (+0.43%)
BABA   72.39 (+1.12%)
T   17.65 (+0.57%)
F   13.26 (+1.53%)
MU   117.96 (-0.99%)
CGC   8.63 (-9.63%)
GE   175.78 (-2.41%)
DIS   122.38 (+1.16%)
AMC   3.66 (-15.67%)
PFE   27.86 (+0.29%)
PYPL   67.25 (+1.02%)
XOM   116.08 (+0.97%)

Exact Sciences (EXAS) Stock Price, News & Analysis

$70.03
+3.15 (+4.71%)
(As of 03:16 PM ET)
Today's Range
$67.18
$71.62
50-Day Range
$56.27
$66.88
52-Week Range
$56.05
$100.77
Volume
4.33 million shs
Average Volume
2.01 million shs
Market Capitalization
$12.71 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$99.31

Exact Sciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.85 Rating Score
Upside/​Downside
42.3% Upside
$99.31 Price Target
Short Interest
Healthy
3.59% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.83
Upright™ Environmental Score
News Sentiment
0.93mentions of Exact Sciences in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$4.10 M Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.65 out of 5 stars

Medical Sector

84th out of 939 stocks

Medical Laboratories Industry

4th out of 20 stocks

EXAS stock logo

About Exact Sciences Stock (NASDAQ:EXAS)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

EXAS Stock Price History

EXAS Stock News Headlines

3 Hot Stocks Bought by Members of Congress: Follow the Money
The STOCK Act of 2012 was supposed to halt insider trading by members of Congress, but let's be honest. The STOCK Act can't really stop Congresspeople from trading on insider knowledge; they're in a position to get it, which will influence investment decisions.
3 Hot Stocks Bought by Members of Congress: Follow the Money (EXAS)
Palo Alto Networks, Simon Property Group and JPMorgan Chase are the top three stocks bought by Members of Congress in February;
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
3 Growth Stocks to Buy at 52-Week Lows in March
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Exact Sciences Unusual Options Activity
EXAS Apr 2024 50.000 put
EXAS Jul 2024 42.500 put
7 Stable Stocks to Buy for 100% Returns by 2025
7 Stable Stocks to Buy for 100% Returns by 2025
See More Headlines
Receive EXAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/21/2024
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:EXAS
CUSIP
30063P10
Employees
6,600
Year Founded
1995

Price Target and Rating

Average Stock Price Target
$99.31
High Stock Price Target
$130.00
Low Stock Price Target
$73.00
Potential Upside/Downside
+41.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.85
Research Coverage
13 Analysts

Profitability

Net Income
$-204,150,000.00
Pretax Margin
-8.07%

Debt

Sales & Book Value

Annual Sales
$2.50 billion
Cash Flow
$0.02 per share
Book Value
$17.39 per share

Miscellaneous

Free Float
179,171,000
Market Cap
$12.71 billion
Optionable
Optionable
Beta
1.22

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

EXAS Stock Analysis - Frequently Asked Questions

Should I buy or sell Exact Sciences stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last twelve months. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" EXAS shares.
View EXAS analyst ratings
or view top-rated stocks.

What is Exact Sciences' stock price target for 2024?

13 equities research analysts have issued 1 year price targets for Exact Sciences' stock. Their EXAS share price targets range from $73.00 to $130.00. On average, they anticipate the company's share price to reach $99.31 in the next year. This suggests a possible upside of 42.3% from the stock's current price.
View analysts price targets for EXAS
or view top-rated stocks among Wall Street analysts.

How have EXAS shares performed in 2024?

Exact Sciences' stock was trading at $73.98 on January 1st, 2024. Since then, EXAS shares have decreased by 5.6% and is now trading at $69.81.
View the best growth stocks for 2024 here
.

Are investors shorting Exact Sciences?

Exact Sciences saw a decline in short interest in March. As of March 15th, there was short interest totaling 6,520,000 shares, a decline of 7.4% from the February 29th total of 7,040,000 shares. Based on an average trading volume of 1,940,000 shares, the short-interest ratio is currently 3.4 days.
View Exact Sciences' Short Interest
.

When is Exact Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our EXAS earnings forecast
.

How were Exact Sciences' earnings last quarter?

Exact Sciences Co. (NASDAQ:EXAS) issued its quarterly earnings results on Wednesday, February, 21st. The medical research company reported ($0.27) EPS for the quarter, beating analysts' consensus estimates of ($0.53) by $0.26. The medical research company had revenue of $646.89 million for the quarter, compared to the consensus estimate of $638.83 million. Exact Sciences had a negative trailing twelve-month return on equity of 6.60% and a negative net margin of 8.17%. The company's revenue was up 17.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.72) earnings per share.

What guidance has Exact Sciences issued on next quarter's earnings?

Exact Sciences issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.8 billion-$2.9 billion, compared to the consensus revenue estimate of $2.8 billion.

What is Kevin T. Conroy's approval rating as Exact Sciences' CEO?

328 employees have rated Exact Sciences Chief Executive Officer Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among the company's employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 69.0% of employees surveyed would recommend working at Exact Sciences to a friend.

What other stocks do shareholders of Exact Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Salesforce (CRM), PayPal (PYPL), Block (SQ), Advanced Micro Devices (AMD), Walt Disney (DIS) and AbbVie (ABBV).

Who are Exact Sciences' major shareholders?

Exact Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.71%), Vanguard Group Inc. (9.67%), Capital World Investors (4.13%), ARK Investment Management LLC (3.34%), Artisan Partners Limited Partnership (2.47%) and Baillie Gifford & Co. (2.08%). Insiders that own company stock include Brian Baranick, Canada Pension Plan Investment, D Scott Coward, Daniel J Levangie, Everett Cunningham, Jacob A Orville, James Edward Doyle, James Herriott, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy and Sarah Condella.
View institutional ownership trends
.

How do I buy shares of Exact Sciences?

Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Exact Sciences have any subsidiaries?
The following companies are subsidiares of Exact Sciences: Armune BioScience, Ashion Analytics, Base Genomics Limited, Biomatrica Inc., Exact Sciences Development Company LLC, Exact Sciences Laboratories LLC, Genomic Health Inc., Genomic Health International Holdings LLC, Paradigm Diagnostics Inc., Sampleminded Inc., Thrive Earlier Detection Corporation, and Viomics Inc..
Read More
This page (NASDAQ:EXAS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners